Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00012298 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

81

Enrollment

NIH

Sponsor class

Stopped Trial completed prematurely.

Conditions

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Small Lymphocytic Lymphoma
Splenic Marginal Zone Lymphoma
Waldenström Macroglobulinemia

Interventions

BIOLOGICAL: rituximab
BIOLOGICAL: yttrium Y 90 ibritumomab tiuxetan
BIOLOGICAL: indium In 111 ibritumomab tiuxetan
BIOLOGICAL: oprelvekin
BIOLOGICAL: filgrastim

Sponsor

National Cancer Institute (NCI)